Background
Methods
Statistical analysis
Results
Baseline characteristics
Group A. In-house (n = 50) | Group B. Referred (n = 50) | P value | |
---|---|---|---|
Mean age (years) ± SD | 58.13 ± 12.81 | 58.74 ± 13.29 | 0.41 |
Mean baseline BCVA logMAR (ETDRS equivalent) ± SD | 1.99 (20/1954) ± 0.61 | 1.96 (20/1824) ± 0.45 | 0.48 |
Male: Female | 29: 21 | 26: 24 | 0.55 |
Mean event to report time days (± SD, 95% CI) | 6.83 (±7.61; 95% CI, 4.57 – 9.09) | 13.63 (±11.67; 95% CI, 9.95 – 17.31) | 0.002* |
Number of diabetics | 6 | 2 | 0.14 |
Inflammatory score (Mean ± SD) | 17.85 ± 5.83 | 18.18 ± 7.35 | 0. 24 |
Final best corrected visual acuity | |||
≥ 20/200 | 29 of 48 (60.42%; 95% CI, 45.30-73.89) | 22 of 50 (44%; 95% CI, 30.27-58.65) | 0.11 |
≤ 20/400 | 18 of 48 (37.5%; 95% CI, 24.32-54.67) | 26 of 50 (52%; 95% CI, 37.58-66.12) | 0.62 |
Visual outcome at last visit
Microbiological profile
Isolate | Number | |||
---|---|---|---|---|
Group A In-house (N = 50) | Group B Referred (N = 50) | |||
Gram positive (n = 31 in A, n = 19 in B, P = 0.027a) |
Staphylococcus
| Coagulase negative Staphylococcus
| 5 | 9 |
Staphylococcus epidermidis
| 7 | 2 | ||
Staphylococcus aureus
| 5 | 0 | ||
Total | 17 | 11 | ||
Streptococcus
|
Streptococcus pneumoniae
| 9 | 2 | |
Streptococcus species | 2 | 1 | ||
Total | 11 | 3 | ||
Others |
Bacillus species | 3 | 1 | |
Corynebacterium species
| 0 | 2 | ||
Nocardia species
| 0 | 2 | ||
Total | 3 | 5 | ||
Gram negative (n = 12 in A, n = 26 in B, P = 0.007a) |
Pseudomonas
|
Pseudomonas aeruginosa
| 8 | 11 |
Pseudomonas species | 0 | 5 | ||
Total | 8 | 16 | ||
Others |
Enterobacteriaceae
| 4 | 4 | |
Other Gram negative bacteria | 0 | 6 | ||
Total | 4 | 10 | ||
Others | Fungi | Fungi | 4 | 4 |
Mixed infections | Multiple bacteria | 1 | 1 | |
Bacterium + Fungus | 2 | 0 | ||
Total | 3 | 1 |
Antibiotic-sensitivity profile
Ceftazidime resistance
S No. | Endophthalmitis isolate | Amikacin | Imipenem | Chloramphenicol | Ciprofloxacin | Gatifloxacin | Moxifloxacin | Ofloxacin | Tobramycin |
---|---|---|---|---|---|---|---|---|---|
Group A | |||||||||
1 |
Eschericia coli
| I | S | S | R | I | R | R | NT |
2 |
Enterobacter cloacae
| S | S | S | I | S | I | S | R |
3 |
Enterobacter cloacae
| S | S | R | I | S | I | S | R |
4 |
Pseudomonas aeruginosa
| R | S | R | R | R | R | NT | NT |
5 |
Pseudomonas aeruginosa
| R | S | R | R | R | R | NT | NT |
Group B | |||||||||
1 |
Achromobacter xylosoxidans
| S | NT | S | S | S | S | S | S |
2 |
Eschericia coli
| S | NT | S | S | S | S | S | S |
3 |
Klebsiela pneumoniae
| S | S | R | R | R | R | R | S |
4 |
Pseudomonas aeruginosa
| R | S | R | R | R | R | R | R |
5 |
Pseudomonas species
| S | NT | S | S | S | S | S | S |
6 |
Pseudomonas stutzeri
| R | NT | S | S | S | R | S | R |
7 |
Pseudomonas stutzeri
| S | R | R | R | R | R | R | S |
8 |
Sphingomonas paucimobilis
| S | NT | S | R | S | R | S | S |
9 |
Stenotrphomonas maltophilia
| S | NT | S | S | S | S | S | S |
Prior therapy
S no. | Age (years) | Prior intervention | Presenting BCVA | Our intervention | Organism | Sensitivity | Final BCVA |
---|---|---|---|---|---|---|---|
1 | 70 | IOAB | LP | PPV + 2x IOAB |
P. aeroginosa
| Sensitive to amikacin, ceftazidime, gatifloxacin, moxifloxacin, cirprofloxacin, and ofloxacin Resistant to chloramphenicol | LP |
2 | 10 | 2x IOAB | LP | PPV + 2x IOAB |
Streptococcus pyogenes
| Sensitive to vanomycin, gatifloxacin, moxifloxacin, cirprofloxacin, and ofloxacin Resistant to amikacin | |
3 | 64 | AC wash + IOAB | LP | Vitreous biopsy + 5x IOAB |
P. aeruginosa
| Sensitive to amikacin, ceftazidime, gatifloxacin, moxifloxacin, cirprofloxacin, and ofloxacin Resistant to tobramycin | LP |
4 | 62 | Vitreous biosy + IOAB | 6/36 | PPV + 2x IOAB |
R. radiobacter
| Sensitive to amikacin, ceftazidime, gatifloxacin, moxifloxacin, cirprofloxacin, ofloxacin Resistant to chloramphenicol | 6/36 |
5 | 55 | 2x IOAB | 6/36 | PPV + IOAB + 2x Intravitreal Amphoterecin B |
C. pelliculosa
| — | 6/15 |